Sales growth was driven by continued strong execution on priority brands including Kisqali (+68% cc), Kesimpta (+44% cc), Pluvicto (+45% cc) and Scemblix (+95% cc) Core operating income margin 1 was ...
Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease 2, at a late-breaker presentation during the American ...
Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases; ...
. Novartis is providing the information in this press release as of this date, and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release ...
Sprawdź aktualne oferty i ubiegaj się o pracę w spółkach Grupy Novartis na całym świecie. Nawigacja Novartis Poland ...
Atklājiet darba iespējas Novartis. Lai atrastu papildu Novartis Gene Therapies (agrāk AveXis) darba piedāvājumus, apmeklējiet GTx karjeras meklēšanas lapu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback